1 |
33634586 |
10.1002/cyto.b.21995 |
2022 |
Flow cytometry detection of CD138 expression continuum between monotypic B and plasma cells is associated with both high IgM peak levels and MYD88 mutation and contributes to diagnosis of Waldenström macroglobulinemia. |
CXCR4 |
2 |
34115701 |
10.1097/RLU.0000000000003750 |
2022 |
Burkitt Lymphoma/Leukemia Presented on 68Ga-Pentixafor and 18F-FDG PET/CT. |
CXCR4 |
3 |
34525196 |
10.1182/blood.2021013239 |
2022 |
CXCR4 PET/MRI for follow-up of gastric mucosa-associated lymphoid tissue lymphoma after first-line Helicobacter pylori eradication. |
CXCR4 |
4 |
34651291 |
10.1007/s11307-021-01664-3 |
2022 |
CXCR4-Directed PET/CT with [<sup>68</sup>Ga]Pentixafor in Central Nervous System Lymphoma: A Comparison with [<sup>18</sup>F]FDG PET/CT. |
CXCR4 |
5 |
34781809 |
10.1080/10428194.2021.2005045 |
2022 |
Plamotamab (XmAb<sup>®</sup>13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenström macroglobulinemia. |
CXCR4 |
6 |
34793256 |
10.1200/JCO.21.01194 |
2022 |
Venetoclax in Previously Treated Waldenström Macroglobulinemia. |
CXCR4 |
7 |
34980578 |
10.1016/j.clml.2021.11.014 |
2022 |
SOHO State of the Art Updates and Next Questions: Waldenström Macroglobulinemia - 2021 Update on Management and Future Directions. |
CXCR4 |
8 |
34990302 |
10.1080/21655979.2021.2017590 |
2022 |
Propofol induces the apoptosis of neural stem cells via microRNA-9-5p / chemokine CXC receptor 4 signaling pathway. |
CXCR4 |
9 |
35020191 |
10.1111/bjh.18036 |
2022 |
Diagnosis and management of Waldenström macroglobulinaemia-A British Society for Haematology guideline. |
CXCR4 |
10 |
35037561 |
10.1080/10428194.2021.2020776 |
2022 |
Clinical effects of a single dose of cannabinoids to patients with chronic lymphocytic leukemia. |
CXCR4 |
11 |
35057088 |
10.3390/pharmaceutics14010192 |
2022 |
Time-Prolonged Release of Tumor-Targeted Protein-MMAE Nanoconjugates from Implantable Hybrid Materials. |
CXCR4 |
12 |
35078860 |
10.1158/1078-0432.CCR-21-3284 |
2022 |
Targeting Refractory Mantle Cell Lymphoma for Imaging and Therapy Using C-X-C Chemokine Receptor Type 4 Radioligands. |
CXCR4 |
13 |
35149375 |
10.1016/j.ctarc.2022.100527 |
2022 |
Current approach to Waldenström Macroglobulinemia. |
CXCR4 |
14 |
35149705 |
10.1038/s41598-022-05857-w |
2022 |
Cell surface expression of GRP78 and CXCR4 is associated with childhood high-risk acute lymphoblastic leukemia at diagnostics. |
CXCR4 |
15 |
35181615 |
|
2022 |
Morphoproteomics Identifies SIRT1, EZH2 and CXCR4 Pathways in Diffuse Large B-Cell Lymphoma: Therapeutic Implications. |
CXCR4 |
16 |
35241482 |
10.2967/jnumed.121.263693 |
2022 |
Imaging of C-X-C Motif Chemokine Receptor 4 Expression in 690 Patients with Solid or Hematologic Neoplasms using <sup>68</sup>Ga-PentixaFor PET. |
CXCR4 |
17 |
35255429 |
10.1016/j.anndiagpath.2021.151886 |
2022 |
De Novo CD5-positive diffuse large B-cell lymphoma: A genomic profiling study and prognostic analysis of 46 patients. |
CXCR4 |
18 |
35316324 |
10.1182/blood.2021014723 |
2022 |
Concurrent CDX2 cis-deregulation and UBTF::ATXN7L3 fusion define a novel high-risk subtype of B-cell ALL. |
CXCR4 |
19 |
35339405 |
10.1016/j.clml.2022.02.005 |
2022 |
SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenström Macroglobulinemia. |
CXCR4 |
20 |
35358350 |
10.1002/ajh.26552 |
2022 |
First- versus second-generation Bruton tyrosine kinase inhibitors in Waldenström's Macroglobulinemia: A systematic review and meta-analysis. |
CXCR4 |
21 |
35385630 |
|
2022 |
Plerixafor on a WHIM - Promise or Fantasy of a New CXCR4 Inhibitor for This Rare, but Important Syndrome? |
CXCR4 |
22 |
35421785 |
10.1016/j.biopha.2022.112940 |
2022 |
A diphtheria toxin-based nanoparticle achieves specific cytotoxic effect on CXCR4<sup>+</sup> lymphoma cells without toxicity in immunocompromised and immunocompetent mice. |
CXCR4 |
23 |
35450208 |
10.1177/20406207221090886 |
2022 |
Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib. |
CXCR4 |
24 |
35454017 |
10.3390/diagnostics12040969 |
2022 |
Nucleic Acid Biomarkers in Waldenström Macroglobulinemia and IgM-MGUS: Current Insights and Clinical Relevance. |
CXCR4 |
25 |
35510210 |
10.1177/20406207221093962 |
2022 |
Treatment paradigm in Waldenström macroglobulinemia: frontline therapy and beyond. |
CXCR4 |
26 |
35522562 |
10.1002/path.5924 |
2022 |
CXCR4 mediates leukemic cell migration and survival in the testicular microenvironment. |
CXCR4 |
27 |
35608747 |
10.1007/s11033-022-07163-0 |
2022 |
Molecular effects of genistein, as a potential anticancer agent, on CXCR-4 and VEGF pathway in acute lymphoblastic leukemia. |
CXCR4 |
28 |
35674738 |
10.1007/s00259-022-05849-y |
2022 |
CXCR4-targeted theranostics in oncology. |
CXCR4 |
29 |
35695746 |
10.1080/17474086.2022.2089110 |
2022 |
Positron emission tomography/magnetic resonance imaging (PET/MRI) vs. gastroscopy: Can it improve detection of extranodal marginal zone lymphomas of the stomach following <i>H. pylori</i> treatment? |
CXCR4 |
30 |
35738903 |
10.2967/jnumed.122.264207 |
2022 |
C-X-C Motif Chemokine Receptor 4-Targeted Radioligand Therapy in Patients with Advanced T-Cell Lymphoma. |
CXCR4 |
31 |
35770040 |
10.2147/TCRM.S338655 |
2022 |
Zanubrutinib in Treating Waldenström Macroglobulinemia, the Last Shall Be the First. |
CXCR4 |
32 |
35774848 |
10.1155/2022/3276925 |
2022 |
Identification of CXCR4 Upregulation in Diffuse Large B-Cell Lymphoma Associated with Prognostic Significance and Clinicopathological Characteristics. |
CXCR4 |
33 |
35794478 |
10.1038/s41586-022-04906-8 |
2022 |
Super-enhancer hypermutation alters oncogene expression in B cell lymphoma. |
CXCR4 |
34 |
35802888 |
10.1080/10428194.2022.2074986 |
2022 |
CXCR4 expression of multiple myeloma as a dynamic process: influence of therapeutic agents. |
CXCR4 |
35 |
35842683 |
10.1186/s13287-022-03011-x |
2022 |
Prostaglandin E1 reduces apoptosis and improves the homing of mesenchymal stem cells in pulmonary arterial hypertension by regulating hypoxia-inducible factor 1 alpha. |
CXCR4 |
36 |
35877223 |
10.3390/curroncol29070363 |
2022 |
Concurrent Waldenstrom's Macroglobulinemia and Myelodysplastic Syndrome with a Sequent t(10;13)(p13;q22) Translocation. |
CXCR4 |
37 |
35884548 |
10.3390/cancers14143488 |
2022 |
Clinical Applications of Immuno-PET in Lymphoma: A Systematic Review. |
CXCR4 |
38 |
35954476 |
10.3390/cancers14153814 |
2022 |
The Role of [<sup>68</sup>Ga]Ga-Pentixafor PET/CT or PET/MRI in Lymphoma: A Systematic Review. |
CXCR4 |
39 |
36030395 |
10.1111/ejh.13856 |
2022 |
A comparison of four leukapheresis methods to harvest an optimal dose of CD34+ cells: A single center experience. |
CXCR4 |
40 |
36048893 |
10.1093/ajcp/aqac104 |
2022 |
Systemic Presentation of Somatic TET2 Mutated B-Cell Lymphoma in a Child With Kabuki Syndrome and a Germline KMT2D Variant. |
CXCR4 |
41 |
32733009 |
10.1038/s41375-020-0999-2 |
2021 |
Cross-talk between GLI transcription factors and FOXC1 promotes T-cell acute lymphoblastic leukemia dissemination. |
CXCR4 |
42 |
32795528 |
10.1016/j.jid.2020.06.034 |
2021 |
Cancer-Associated Fibroblasts in Mycosis Fungoides Promote Tumor Cell Migration and Drug Resistance through CXCL12/CXCR4. |
CXCR4 |
43 |
32810857 |
10.1159/000509286 |
2021 |
Current and Emerging Treatments for Waldenström Macroglobulinemia. |
CXCR4 |
44 |
33131073 |
10.1111/exd.14228 |
2021 |
The role of Dipeptidyl Peptidase-4 in cutaneous disease. |
CXCR4 |
45 |
33206936 |
10.1182/blood.2020005650 |
2021 |
Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia. |
CXCR4 |
46 |
33208624 |
10.1097/RLU.0000000000003404 |
2021 |
Assessment of Central Nervous System Lymphoma Based on CXCR4 Expression In Vivo Using 68Ga-Pentixafor PET/MRI. |
CXCR4 |
47 |
33253591 |
10.1021/acs.molpharmaceut.0c00785 |
2021 |
High-Contrast CXCR4-Targeted <sup>18</sup>F-PET Imaging Using a Potent and Selective Antagonist. |
CXCR4 |
48 |
33391493 |
10.7150/thno.48620 |
2021 |
CXCR4 PET imaging of mantle cell lymphoma using [<sup>68</sup>Ga]Pentixafor: comparison with [<sup>18</sup>F]FDG-PET. |
CXCR4 |
49 |
33555272 |
10.1172/JCI141566 |
2021 |
RUNX2 regulates leukemic cell metabolism and chemotaxis in high-risk T cell acute lymphoblastic leukemia. |
CXCR4 |
50 |
33569985 |
10.1080/10428194.2021.1881514 |
2021 |
Clinical application of genomics in Waldenström macroglobulinemia. |
CXCR4 |
51 |
33579803 |
10.2967/jnumed.120.257279 |
2021 |
Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT. |
CXCR4 |
52 |
33604348 |
10.3389/fmed.2021.609116 |
2021 |
YF-H-2015005, a CXCR4 Antagonist, for the Mobilization of Hematopoietic Stem Cells in Non-Hodgkin Lymphoma Patients: A Randomized, Controlled, Phase 3 Clinical Trial. |
CXCR4 |
53 |
33612450 |
10.1016/j.transci.2021.103070 |
2021 |
First experience of the use of a generic of plerixafor in peripheral blood stem cell mobilization in multiple myeloma and lymphoma patients. |
CXCR4 |
54 |
33660512 |
10.1021/acs.jmedchem.1c00066 |
2021 |
Novel Peptide-Based PET Probe for Non-invasive Imaging of C-X-C Chemokine Receptor Type 4 (CXCR4) in Tumors. |
CXCR4 |
55 |
33716502 |
10.2147/IJN.S289733 |
2021 |
Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4<sup>+</sup> Diffuse Large B-Cell Lymphoma Cells. |
CXCR4 |
56 |
33735664 |
10.1016/j.neo.2021.02.002 |
2021 |
Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia. |
CXCR4 |
57 |
33743810 |
10.1186/s13045-021-01060-y |
2021 |
Targeting chemokines for acute lymphoblastic leukemia therapy. |
CXCR4 |
58 |
33843403 |
10.1080/10428194.2021.1910684 |
2021 |
CXCR4 allows T cell acute lymphoblastic leukemia to escape from JAK1/2 and BCL2 inhibition through CNS infiltration. |
CXCR4 |
59 |
33856274 |
10.1080/10428194.2021.1913150 |
2021 |
Different chemokine profile between systemic and testicular diffuse large B-cell lymphoma. |
CXCR4 |
60 |
33934404 |
10.1002/jcla.23784 |
2021 |
PCR array analysis identified hyperproliferation but not autophagy or apoptosis in fibrous epulis. |
CXCR4 |
61 |
34050566 |
10.1111/cpr.13076 |
2021 |
Role of CXCR4 in the progression and therapy of acute leukaemia. |
CXCR4 |
62 |
34083646 |
10.1038/s41598-021-91112-7 |
2021 |
DC-SIGN binding to mannosylated B-cell receptors in follicular lymphoma down-modulates receptor signaling capacity. |
CXCR4 |
63 |
34093792 |
10.7150/jca.54952 |
2021 |
Aggregative Perivascular Tumor Cell Growth Pattern of Primary Central Nervous System Lymphomas Is Associated with Hypoxia-Related Endoplasmic Reticulum Stress. |
CXCR4 |
64 |
34106998 |
10.1371/journal.ppat.1009618 |
2021 |
Epigenetic Plasticity Enables CNS-Trafficking of EBV-infected B Lymphocytes. |
CXCR4 |
65 |
34122453 |
10.3389/fimmu.2021.688747 |
2021 |
Knowledge From London and Berlin: Finding Threads to a Functional HIV Cure. |
CXCR4 |
66 |
34172595 |
10.1097/RLU.0000000000003760 |
2021 |
Chemokine Receptor 4-Targeted 68Ga-Pentixafor PET/CT in Response Assessment of Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: Comparison to 18F-FDG PET/CT. |
CXCR4 |
67 |
34187383 |
10.1186/s12876-021-01844-z |
2021 |
Tumor-to-tumor metastasis of diffuse large B cell lymphoma to gastric adenocarcinoma via CXCL12 (SDF-1)/CXCR4 axis: a case report. |
CXCR4 |
68 |
34255748 |
10.1172/JCI143119 |
2021 |
Nuclear PFKP promotes CXCR4-dependent infiltration by T cell acute lymphoblastic leukemia. |
CXCR4 |
69 |
34269725 |
10.1097/RLU.0000000000003817 |
2021 |
CXCR4 Expression Demonstrated by 68Ga-Pentixafor PET/CT Imaging in a Case of Systemic Mastocytosis Mimicking Lymphoma. |
CXCR4 |
70 |
34307181 |
10.3389/fonc.2021.710900 |
2021 |
Somatostatin Receptors and Chemokine Receptor CXCR4 in Lymphomas: A Histopathological Review of Six Lymphoma Subtypes. |
CXCR4 |
71 |
34340248 |
10.1111/bjh.17691 |
2021 |
Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemia. |
CXCR4 |
72 |
34363012 |
10.1038/s41375-021-01376-1 |
2021 |
CXCR4 hyperactivation cooperates with TCL1 in CLL development and aggressiveness. |
CXCR4 |
73 |
34396983 |
10.1172/JCI151295 |
2021 |
All in for nuclear PFKP-induced CXCR4 metastasis: a T cell acute lymphoblastic leukemia prognostic marker. |
CXCR4 |
74 |
34404617 |
10.1016/j.transci.2021.103240 |
2021 |
An innovation in stem cell harvesting: Heparin use. |
CXCR4 |
75 |
34490994 |
10.1002/pbc.29319 |
2021 |
Single-center results reporting improved hematopoietic stem cell mobilization success in pediatric and young adult patients with solid tumors and lymphoma. |
CXCR4 |
76 |
34570179 |
10.1182/bloodadvances.2021004668 |
2021 |
Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies. |
CXCR4 |
77 |
34583709 |
10.1186/s12943-021-01419-2 |
2021 |
Single-cell RNA sequencing reveals markers of disease progression in primary cutaneous T-cell lymphoma. |
CXCR4 |
78 |
34635806 |
10.1038/s41423-021-00775-9 |
2021 |
Posttransplant blockade of CXCR4 improves leukemia complete remission rates and donor stem cell engraftment without aggravating GVHD. |
CXCR4 |
79 |
34714390 |
10.1186/s13550-021-00852-0 |
2021 |
Semi-quantitative measurements of chemokine receptor 4-targeted <sup>68</sup>Ga-pentixafor PET/CT in response assessment of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma. |
CXCR4 |
80 |
34722241 |
10.3389/fonc.2021.692788 |
2021 |
Predictive and Prognostic Biomarkers for Lung Cancer Bone Metastasis and Their Therapeutic Value. |
CXCR4 |
81 |
34793563 |
10.1371/journal.pone.0260186 |
2021 |
Investigating CXCR4 expression of tumor cells and the vascular compartment: A multimodal approach. |
CXCR4 |
82 |
34990523 |
10.4143/crt.2021.944 |
2021 |
Predictive Parameters of Febrile Neutropenia and Clinical Significance of G-CSF Receptor Signaling Pathway in the Development of Neutropenia During R-CHOP Chemotherapy with Prophylactic Pegfilgrastim in Patients with Diffuse Large B-Cell Lymphoma. |
CXCR4 |
83 |
35028611 |
10.1016/j.xcrm.2021.100470 |
2021 |
Targeted blockade of immune mechanisms inhibit B precursor acute lymphoblastic leukemia cell invasion of the central nervous system. |
CXCR4 |
84 |
35087759 |
10.3389/fonc.2021.801124 |
2021 |
Determinants of Drug Resistance in B-Cell Non-Hodgkin Lymphomas: The Case of Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia. |
CXCR4 |
85 |
31248974 |
10.3324/haematol.2018.211490 |
2020 |
A CXCR4-targeted nanocarrier achieves highly selective tumor uptake in diffuse large B-cell lymphoma mouse models. |
CXCR4 |
86 |
31260155 |
10.1002/jmri.26848 |
2020 |
MRI and PET/MRI in hematologic malignancies. |
CXCR4 |
87 |
31471373 |
10.3324/haematol.2019.216218 |
2020 |
CXCR4 upregulation is an indicator of sensitivity to B-cell receptor/PI3K blockade and a potential resistance mechanism in B-cell receptor-dependent diffuse large B-cell lymphomas. |
CXCR4 |
88 |
31476465 |
10.1016/j.wneu.2019.08.140 |
2020 |
T140 Inhibits Apoptosis and Promotes Proliferation and Matrix Formation Through the SDF-1/CXC Receptor-4 Signaling Pathway in Endplate Chondrocytes of the Rat Intervertebral Discs. |
CXCR4 |
89 |
31561267 |
10.1002/1873-3468.13623 |
2020 |
Single-cell RNA sequencing reveals chemokine self-feeding of myeloma cells promotes extramedullary metastasis. |
CXCR4 |
90 |
31571524 |
10.1080/15384047.2019.1665405 |
2020 |
CXCR4-targeted PET imaging using <sup>64</sup>Cu-AMD3100 for detection of Waldenström Macroglobulinemia. |
CXCR4 |
91 |
31605845 |
10.1016/j.wneu.2019.09.158 |
2020 |
Primary Intra-Axial Diffuse Large B-Cell Lymphoma in Immunocompetent Patients: Clinical Impact of Molecular Analysis and Histogenetic Evaluation. |
CXCR4 |
92 |
31719683 |
10.1038/s41375-019-0628-0 |
2020 |
Physiological levels of the PTEN-PI3K-AKT axis activity are required for maintenance of Burkitt lymphoma. |
CXCR4 |
93 |
31726164 |
10.1016/j.ijbiomac.2019.09.157 |
2020 |
Degraded fucoidan fractions and β-1,3-glucan sulfates inhibit CXCL12-induced Erk1/2 activation and chemotaxis in Burkitt lymphoma cells. |
CXCR4 |
94 |
31768009 |
10.1038/s41409-019-0756-1 |
2020 |
The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma. |
CXCR4 |
95 |
31809874 |
10.1016/j.cellsig.2019.109492 |
2020 |
Ghrelin induces autophagy and CXCR4 expression via the SIRT1/AMPK axis in lymphoblastic leukemia cell lines. |
CXCR4 |
96 |
31902622 |
10.1016/j.pathol.2019.11.002 |
2020 |
A practical guide to laboratory investigations at diagnosis and follow up in Waldenström macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group. |
CXCR4 |
97 |
31960730 |
10.1080/10428194.2020.1711901 |
2020 |
Waldenstrom's macroglobulinemia in the era of immunotherapy. |
CXCR4 |
98 |
31980558 |
10.1136/jclinpath-2019-206282 |
2020 |
Diagnostic value of bone marrow core biopsy patterns in lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia and description of its mutational profiles by targeted NGS. |
CXCR4 |
99 |
32006301 |
10.1007/s11899-020-00559-4 |
2020 |
Novel Treatment Strategies in the Management of Waldenström Macroglobulinemia. |
CXCR4 |
100 |
32083995 |
10.1200/JCO.19.02314 |
2020 |
Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies. |
CXCR4 |